IND-enabling studies of PM-208: a novel pre-hospital anti-shock therapeutic
Active Definitive Contract Awarded Last action
- Contract number
- HT942726CE025
- Awardee
-
Perfusion Medical, Inc. UEI XEDJGXP1K889
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $1,499,773
Award facts
- Opportunity
-
- HQ003420RBDST Solicitation number
- Contract value 100% obligated
- $1,499,773.00 Current and potential, with all options
- Completion date 44% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Herndon, VA 20170, USA
- Research
- SBIR Program Phase II Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $1,499,773 |
About this award
The Defense Health Agency awarded a $1.499 million definitive contract to Perfusion Medical, Inc. on April 10, 2026, for investigational new drug-enabling studies of polyethylene glycol 20K/8K IV solution, a novel pre-hospital anti-shock therapeutic, under a total small business set-aside.
Place of performance is Herndon, VA. The contract extends through August 9, 2027. Perfusion Medical is a small biotechnology company developing patented intravenous therapeutics for acute medical emergencies, with federal work focused on IND-enabling research supporting the clinical advancement of PM-208 for treatment of septic shock, hemorrhagic shock, and acute kidney injury in pre-hospital and field settings. The company's core technology originated at Virginia Commonwealth University and benefits from clinical collaboration with Mayo Clinic and Virginia Commonwealth University on dosing optimization and mechanistic research into tissue perfusion preservation during sepsis. This award reflects the Defense Health Agency's continued investment in Perfusion Medical's regulatory pathway, following a prior $2.99 million SBIR Phase II contract for the same therapeutic candidate that completed in July 2026.
Quick answers
Who was awarded contract HT942726CE025?
HT942726CE025 was awarded to Perfusion Medical, Inc. by Defense Health Agency (Department of Defense) on April 2, 2026.
How much is contract HT942726CE025 worth?
The government has obligated $1,499,773 on HT942726CE025.
Was contract HT942726CE025 competed?
The extent of competition for HT942726CE025 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award